Condition: Advanced Melanoma · Melanoma Metastatic · Sarcoma · Sponsor: Centre Hospitalier Universitaire Vaudois
A single center, dose escalaion, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous "New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor (NY-ESO-1 TCR)-directed T cells in combination with non-myeloablative (NMA) lymphodepleting chemotherapy and low dose irradiation (LDI) in patients with NY-ESO-1 positive sarcoma and melanoma.
This description comes directly from the study's public registry record.
Bernhard Gentner, MD · +4179 556 90 20 · Bernhard.Gentner@chuv.ch
Virginie Zimmer, Study Coordinator · +41 21 314 97 09 · virginie.zimmer@chuv.ch
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Universitaire Vaudois (CHUV) | Lausanne, Canton of Vaud, Switzerland | Not Yet Recruiting |
| Centre Hospitalier Universitaire Vaudois | Lausanne, Canton of Vaud, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06889766